Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Two-Part, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of KER-012 Administered to Healthy, Postmenopausal Women

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cibotercept (Primary)
  • Indications Osteoporosis; Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Keros Therapeutics

    • Most Recent Events

    • 29 Jan 2024 According to a Keros Therapeutics media release, data from this study will be presented at the Pulmonary Vascular Research Institute 2024 Annual Congress
    • 28 Aug 2023 Results assessing the safety and tolerability of KER-012 in healthy post-menopausal women, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 24 May 2023 Results assessing the safety of KER-012 in healthy post-menopausal women, presented at the 119th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top